More Clinical Articles


Greater Transparency & Collaboration Critical to Drug Discovery

Zuzanna Fimińska, (Feb 11, 2015)

Scientific and organizational challenges are crippling pharma’s drug discovery efforts. Introducing new drugs depends on the industry’s ability to pool resources, cooperate, and embrace transparency.

Leveraging Big Data to simplify clinical trials and fix R&D

Zuzanna Fimińska, (Feb 6, 2015)

Pharma needs to embrace Big Data and technology solutions that facilitate trials to cure R&D stagnation.

Getting value from oral oncolytics

Adam Hill, (Feb 2, 2015)

Oral cancer drugs can offer a more convenient alternative to traditional IV therapies when it comes to treating patients, but issues such as adherence and reimbursement still need to be ironed out, while payers have to be convinced that oral agents represent value for money.

Translating Patient Centricity into Organizational Reality

Adam Hill, (Jan 22, 2015)

Positive patient experiences and patient outcomes with high recruitment, adherence and retention result from alignment of the HEART, HEAD and HANDS within the research sponsor’s organization and among all key stakeholders.

Open Data Sharing: Turf Wars v Innovation

Deirdre Coleman, (Jan 13, 2015)

There is consensus around the idea that greater access to patient-level clinical data is a good thing – good for science, business and humanity. However, sharing data brings with it a host of benefits, questions and risks for the industry.

Rebuilding Pharma Begins with Patients

Hugo Stephenson, (Jan 8, 2015)

Successfully engaging patients in a clinical trial setting is a challenge. Hugo Stephenson MD, Executive Chairman, DrugDev looks at the key principles of patient engagement that work.

Year in Review 2014: R&D

Zuzanna Fimińska, (Jan 2, 2015)

2014 buzzed with discussion on how to make clinical trials more patient centric. We tried to identify key obstacles to patient enrollment and suggested practical solutions on how to overcome them. We also looked at technologies that will revolutionize R&D and celebrated medical breakthroughs.

Astellas Innovation Challenge to Get Young People into STEM

Zuzanna Fimińska, (Nov 25, 2014)

Although STEM offers exciting career prospects, young people shy away from scientific subjects. Astellas Innovation Challenge aims to change that state of affairs while improving pharma’s image.

Hacking into pharma’s R&D model

Ben Adams, (Nov 24, 2014)

The founder of a new co-op biotech company Andrew Hessel talks to eyeforpharma about how he is planting the seed for major change in the way medicines are discovered.

Orphan drugs: Way to go for pharma?

Zuzanna Fimińska, (Oct 23, 2014)

With drying drug pipelines and increasing competition from generics, the orphan drug sector offers several attractions for pharma. Market exclusivity, protocol assistance, and fee reductions are among some of the benefits offered to the industry on both sides of the Atlantic.